Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

被引：30

作者：

Ardeshna, Kirit M. ^{[1
]}

Marzolini, Maria A. V. ^{[2
]}

Norman, Jane ^{[3
]}

Al-Hajj, Muhammad ^{[4
]}

Thomas, Simon ^{[4
]}

Faulkner, Jim ^{[4
]}

Kotsopoulou, Ekaterini ^{[4
]}

Pule, Martin ^{[4
]}

Peddareddigari, Vijay G. R. ^{[4
]}

Khokhar, Nushmia Z. ^{[4
]}

Jonnaert, Maud ^{[5
]}

Chen, Robert ^{[5
]}

Osborne, Wendy ^{[6
]}

机构：

[1] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England

[2] UCL Canc Inst, London, England

[3] Manchester Univ NHS, Manchester, Lancs, England

[4] Autolus Ltd, London, England

[5] Autolus Therapeut, London, England

[6] Newcastle upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England

来源：

关键词：

D O I：

10.1182/blood-2019-122724

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

246

引用

页数：4